Schilke Tobin 4
4 · Crinetics Pharmaceuticals, Inc. · Filed Mar 11, 2025
Insider Transaction Report
Form 4
Schilke Tobin
Chief Financial Officer
Transactions
- Award
Common Stock
2025-03-10+52,000→ 52,000 total - Award
Stock Option (Right to Buy)
2025-03-10+80,000→ 80,000 totalExercise: $33.75Exp: 2035-03-09→ Common Stock (80,000 underlying)
Footnotes (2)
- [F1]The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2026.
- [F2]The option is exercisable as follows: 25% of the shares subject to the option vest on February 28, 2026, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.